C15 (Pentadecanoic Acid)

C15 (Pentadecanoic Acid)'s downside is mainly uncertainty, opportunity cost, and poor fit in higher-risk situations. The same evidence that makes C15 (Pentadecanoic Acid) interesting also limits overconfidence: Sun et al. 2025 reports prospective and meta-analytic biomarker evidence and observational, not yet a C15:0 supplement trial. Risk tolerance should be lower for pregnancy, complex medical histories, prescription stacking, high-dose use, or chronic use without tracking. Wang et al. 2024 adds the caution lens because it reports preclinical pregnancy and developmental caution and preclinical supplement safety evidence. In practice, C15 (Pentadecanoic Acid) belongs in a simple protocol with one target, one review date, and a willingness to stop when the signal is weak.

Safety Risk (2.0/5.0): Short-term safety looks acceptable at 200 mg/day, but the evidence base is too small to establish long-term safety. The two direct human trials lasted 12 weeks and combined only 118 participants, which is far below what is needed to catch rare or delayed problems. Wang 2024 adds a cautionary animal pregnancy signal involving mild maternal glucose intolerance and offspring pathway changes. That does not prove human harm, but it does make pregnancy and lactation inappropriate use cases. FDA supplement status also means no premarket safety and effectiveness approval.

Side Effect Profile (1.5/5.0): Published human trials have not shown a major side-effect burden at 200 mg/day for 12 weeks, which keeps this dimension low. The limitation is statistical power. A combined n=118 cannot meaningfully characterize uncommon side effects, drug interactions, LDL responses, or longer-term metabolic shifts. User reports outside trials include occasional gastrointestinal complaints and lipid concerns, but those are uncontrolled and cannot be used as incidence estimates. The practical answer is simple: short-term tolerance appears good, but anyone testing C15:0 should verify lipid response rather than assume neutrality.

Financial Cost (3.5/5.0): The cost burden is high relative to the evidence. The Fatty15 product page prices C15:0 as a premium subscription, while whole-food dairy can deliver C15:0 plus a broader nutritional matrix for less money. For the same monthly budget, many users could fund better-supported interventions: vitamin D testing and vitamin D3 + K2, omega-3, berberine, creatine, sleep tracking, or higher-quality food. The score is not about capsule convenience. It is about evidence-weighted return per dollar.

Time/Effort Burden (1.2/5.0): C15:0 is mechanically easy: take capsules once daily with a fat-containing meal. The real burden is decision overhead. Users must manage an auto-ship subscription, decide whether to buy the proprietary test bundle, and then interpret small biomarker changes without strong clinical thresholds. For someone already taking several supplements, C15:0 adds another stack slot and another monthly decision. That is still a low effort burden compared with devices, exercise protocols, or strict diets.

Opportunity Cost (3.8/5.0): C15:0 has a high opportunity cost because it targets crowded categories where better options already exist. For fatty liver, diet, weight loss, physical activity, and clinician-guided metabolic care come first. For cardiovascular risk, LDL lowering, blood-pressure control, exercise, sleep, omega-3, and fiber have stronger outcome logic. For longevity, urolithin A and spermidine still need nuance, but they are not built around the same weak essential-fatty-acid premise. The cost is not only money. It is attention.

Dependency / Withdrawal (1.2/5.0): C15:0 has no known withdrawal syndrome, rebound physiology, addictive reward loop, or tolerance pattern. If a user stops, the expected outcome is gradual return of circulating C15:0 toward baseline over weeks. The only dependency is functional: any blood-level increase probably requires ongoing intake. That makes C15:0 more like a maintenance nutrient exposure than a dependency-forming compound. Stopping is straightforward, and a 12-week trial can be ended cleanly if objective markers do not improve.

Reversibility (1.2/5.0): C15:0 supplementation appears highly reversible at the studied dose and duration. There is no evidence of permanent tissue change, irreversible enzyme inhibition, receptor remodeling, or tissue accumulation at 200 mg/day over 12 weeks. Unknown long-term effects are possible because long-term studies do not exist, but the known pharmacology does not imply a hard-to-reverse intervention. A user can stop the supplement, retest labs later, and move the budget to higher-evidence options.